Navigation Links
GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

patients (8) and a need remains for new treatment options.

"These results clearly demonstrate the potential pazopanib offers as a future therapeutic option not only in renal cell cancer, but across many different tumor types," said Debasish Roychowdhury, MD, Vice President, Global Clinical Development, Oncology Medicine Development Centre, GSK. "The broad clinical development program for pazopanib, in various cancers as monotherapy and in combination therapy, including combinations with Tykerb, underscores our continued commitment to delivering effective new treatments for patients with cancer."

Ovarian cancer study (Abstract 5561) (9)

This ongoing Phase II open-label, monotherapy study is evaluating pazopanib in patients with cancer of the ovary, fallopian tube or peritoneum, who have failed standard platinum-based therapy. Treatment is continued until disease progression, withdrawal due to AEs, or withdrawal of consent. Biological activity (measured as a decrease in CA-125, a biologic marker of clinical activity) was seen in nine (41%) of 22 evaluable patients with relapsed disease. The most common AEs were diarrhea, nausea, abdominal pain, fatigue, and vomiting. Please see safety considerations below.

Globally, ovarian cancer (204,000 cases and 125,000 deaths) is the sixth most common cancer and the seventh most common cause of death from cancer in women. (5) The majority of patients with ovarian cancer will have advanced disease at the time of initial diagnosis. Typically, these patients are managed with surgery followed by combination chemotherapy. Although the majority of patients will respond initially to firstline therapy, recurrent disease remains a considerable problem. (10)

Soft tissue sarcoma study (Abstract 10031) (11)

STS is a disease in which malignant cancer cells begin growing in soft tissues, such as muscles, tendons, connective tissues, fat, blood vessels, nerves, and tissues around joints. This ongoing Ph
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:9/19/2014)... , Sept. 19, 2014  Diplomat, the nation,s largest ... David Dreyer to the Board of Directors on ... and will also serve as chair of the Audit ... years of accounting, financial, compliance and operating experience in ... has served as chief financial officer, chief operating officer ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014  Alere Inc. ... rapid diagnostics, issued the following statement today in support ... Antibiotic-Resistant Bacteria. "As the global leader in ... for establishing a national strategy to address the serious ... to work with the Administration on initiatives to promote ...
(Date:9/19/2014)... 19, 2014 Aufgrund der ... äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die ... verfügbar unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen ... in Kraft treten. Für international tätige ... um das "ob", sondern darum, "wann" sie die ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
... Trial Showed REMICADE Therapy is More Likely to Induce ... ... Oct. 6 Data presented for the first time,from the Phase ... Therapy (SONIC) may provide new insights into,the approach to care of ...
... with ... in Clinical Trials -, PHOENIX, Oct. 6 ... focused on the treatment of,obesity and other central nervous ... (naltrexone SR /,bupropion SR), successfully achieved key objectives (lowered ...
Cached Medicine Technology:New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5
(Date:9/19/2014)... New York, NY (PRWEB) September 19, 2014 ... by PR News at the Platinum PR and Top ... Grand Hyatt in New York City. Camino received honorable ... a Shoestring Campaign” — for its work elevating Latina ... with this incredible organization and be a part of ...
(Date:9/19/2014)... of human cancers have abnormally upregulated chemical signals ... are controlled during tumor formation is not fully ... Fayngerts, PhD, both researchers in the department of ... of Medicine, University of Pennsylvania, and colleagues report ... cancer by targeting these pathways. , Lipid second ...
(Date:9/19/2014)... 2014 Hastings and Hastings, a discount accident ... industry, announces a record number of visitors to its new ... of serious injury cases as well as auto accident cases ... related accident cases and others. Having served the state of ... the test of time when it comes to dedicated and ...
(Date:9/19/2014)... with The Melanoma Genetics Consortium, GenoMEL, an international research ... Journal of the National Cancer Institute that proves ... the first time, we have established that the genes ... in the risk of developing melanoma," said lead author ... at the University of Leeds (UK). , Telomeres ...
(Date:9/19/2014)... NJ (PRWEB) September 19, 2014 Visiting ... provider of home health care, hospice and palliative care ... to ring the Opening Bell yesterday at the New ... New Jersey philanthropist and social entrepreneur to care for ... Health Group has always worked to meet the urgent ...
Breaking Medicine News(10 mins):Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:New cancer drug target involving lipid chemical messengers 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Melanoma risk found to have genetic determinant 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3
... MS, ... and sharing her story of hope and determination. , ... Bayfield, WI (PRWEB) April 7, 2010 -- Hopeful climbers have begun streaming in to ... highest peak. Last year,s successful climbers whose summit of Everest also completed their ...
... ... their newest Low level laser for body sculpting. Surprisingly Zerona has also been clinically ... addition to lowering the levels of Lipoprotein (LDL). , ... Houston, TX (PRWEB) April 6, 2010 -- A ...
... ... conversations about your brand, advertising campaign, competitors or product innovations. , ... (PRWEB) April 6, 2010 -- Six ... an easy, affordable way to gather insights needed to optimize marketing strategies, increase advertising ...
... for treatment, at higher rates than expected , TUESDAY, April ... visit hospitals repeatedly in search of treatment, according to new ... of sickle cell patients who visited the hospital returned within ... the ages of 18 and 30, were especially likely to ...
... An approach designed to reduce HIV/STDs previously used ... community-based organizations (CBOs), an important component in national strategies ... "at risk" youths can be reached. , A ... tested whether a proven HIV/STD risk-reduction intervention would work ...
... work better in protecting children from flu if they included ... Louis University research has found. "Adding a second influenza ... some of the guesswork out of strain selection and help ... M.D., lead investigator and director of the Center for Vaccine ...
Cached Medicine News:Health News:Woman with MS Summits Everest and Completes the Seven Summits 2Health News:Woman with MS Summits Everest and Completes the Seven Summits 3Health News:"Zerona" Lipo-Laser Penetrates Wellness Industry for Anti-aging, Weight Loss, Body Sculpting and Cardiac Health 2Health News:"Zerona" Lipo-Laser Penetrates Wellness Industry for Anti-aging, Weight Loss, Body Sculpting and Cardiac Health 3Health News:Sickle Cell Disease Patients Seek Acute Pain Care Repeatedly 2Health News:Sickle Cell Disease Patients Seek Acute Pain Care Repeatedly 3Health News:Roll-out of proven HIV/STD risk-reduction intervention with teens by community groups successful 2Health News:Building a better flu vaccine: Add second strain of influenza B 2
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... are offered as 1-piece or modular, in ... instruments may be customized with handles of ... insulation and flush ports. Many standard patterns ... may affect delivery times. , Please ...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
Medicine Products: